Showing 4061-4070 of 4759 results for "".
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival),
- Humira Talking Pen Launched to Educate on Self-injectionhttps://practicaldermatology.com/news/20120917-humira_talking_pen_launched_to_educate_on_self-injection/2459737/Abbott Laboratories, makers of Humira, released the Humira Talking Training Pen, available at no cost as part of the myHUMIRA patient support program (humira.com/m
- Nomir Medical Submits 510(k) Application to FDA for Onychomycosishttps://practicaldermatology.com/news/20120911-nomir_medical_announces_510k_application_to_fda_for_onychomycosis/2459742/Nomir Medical Technologies, Inc. submitted a 510(k) application to the US Food and Drug Administration (FDA) for the indication of temporary increase of clear nail in patients with onychomycosis (toenail fungus). This 510(k) submission to FDA
- National Rosacea Society to Host 20th Anniversary Galahttps://practicaldermatology.com/news/20120730-national_rosacea_society_to_host_20th_anniversary_gala/2459759/The National Rosacea Society is hosting a 20th Anniversary Gala Celebration and Dinner on August 17, 2012, from 6-9pm at the Boston Sheraton Hotel during the summer AAD meeting to give thanks to the countless healthcare professionals who have helped improve the quality of life for rosacea patients w
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- Cone Health Pioneers Use of Fabric That Healshttps://practicaldermatology.com/news/20120726-cone_health_pioneers_use_of_fabric_that_heals/2459762/Studies find that hospital linens and gowns can be transformed into therapeutic tools when made with a smooth, antimicrobial fabric called DermaTherapy. Researchers found that patients using DermaTherapy developed 81.5 percent fewer be
- gloProfessional Official Uniform Sponsor of Women's USA Field Hockey Teamhttps://practicaldermatology.com/news/20120719-gloprofessional_official_uniform_sponsor_of_womens_usa_field_hockey_team/2459769/The USA field hockey team announced a premier partnership with gloProfessional. The multi-year agreement will feature glo on the front of the Women's National Team jersey and podium suits and represents the first ever corporate advertiser
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- National Eczema Blog Launcheshttps://practicaldermatology.com/news/20120626-national_eczema_blog_launches/2459781/The National Eczema Association recently created a blog featuring guest bloggers on a variety of eczema-related topics. The first post, written by the blogger named “Spanish Key,” provides a patient perspective on eczema research topics and h
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33